SCHEMBL4985136

SCHEMBL4985136

C=CCc1cc(NC(=O)CC)ccc1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.47
GABRB2 P47870 2/20 0.47
GABRA5 P31644 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
HTT P42858 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
ATM Q13315 1/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
ALOX5 P09917 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819280 0.86 GABRA1 (0.58) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL14188849 0.86 GABRA1 (0.45) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL4986308 0.84 RAB9A (0.48) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL3970414 0.79 SMN1; SMN2 (0.68) MAPTLMNAHPGDKMT2APOLB
Hydrochloric Acid SCHEMBL10448976 0.78 SMN1; SMN2 (0.66) MAPTLMNAHPGDKMT2APOLB
SCHEMBL21015681 0.78 GABRA1 (0.52) GABRA1GABRB2GABRA5GABRA3GABRA2
SCHEMBL28332831 0.77 KDM4E (0.45) HTTMAPTKMT2APOLBCYP1A2
SCHEMBL9645055 0.77 HTT (0.60) HTTMAPTKMT2APOLBCYP1A2
SCHEMBL9621556 0.76 TDP1 (0.56) HTTLMNAKMT2APOLBCYP1A2
SCHEMBL3404609 0.76 CYP3A4 (0.69) HTTMAPTLMNAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-05-22 US disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed
EP-1847535-A1 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119518-A1 1-(Piperidin-4- Yl)-1H-Indole Derivatives TPH1, HTR1D, HTR1B GABRA1 1636/4885GABRB2 2261/4885GABRA5 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.